Jazz Pharma Plc (JAZZ) 142.40 $JAZZ Hercules Provides

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Jazz Pharma Plc (JAZZ) 142.40 $JAZZ

Hercules Provides Portfolio Update for Q2 2016 and Highlights Continued Execution of Its Portfolio and Earnings Growth Strategy
BusinessWire - Tue Jul 05, 10:34AM CDT
--Over $6.0 Billion in Total Debt Commitments Milestone achieved (since inception December 2003)
CPXX: 30.25 (+0.01), HTGC: 12.50 (unch), GCI: 13.85 (+0.04), PFE: 36.08 (-0.04), JAZZ: 142.40 (+2.52), ANAC: 99.06 (-0.14), RLOC: 4.56 (unch), EACQ: 9.93 (+0.03)

Jazz Pharmaceuticals Announces Expiration of HSR Waiting Period for Proposed Celator Pharmaceuticals, Inc. Acquisition
PR Newswire Europe - Sun Jun 26, 11:10PM CDT
Jazz Pharmaceuticals plc announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR", with respect to its proposed acquisition of Celator Pharmaceuticals, Inc. expired effective June 24, 2016, at 11:59 p.m. (Eastern Daylight Time).
CPXX: 30.25 (+0.01), JAZZ: 142.40 (+2.52)

After Yesterday's Decline of 2.80%, Jazz Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Tue Jun 21, 2:18PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $139.52 to a high of $144.95. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $142.42 on volume of 400,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JAZZ: 142.40 (+2.52)

Watch for Jazz Pharmaceuticals to Potentially Rebound After Falling 1.10% Yesterday
Comtex SmarTrend(R) - Fri Jun 17, 2:51PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $142.42 to a high of $146.74. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $143.66 on volume of 267,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JAZZ: 142.40 (+2.52)

Jazz Pharmaceuticals Offers HAL Study Data on JZP-110
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 8:42AM CDT
Jazz (JAZZ) presented new data from a Human Abuse Liability (HAL) study on JZP-110 at the annual meeting of the Associated Professional Sleep Societies.
ANIP: 56.50 (-0.01), JAZZ: 142.40 (+2.52), PFE: 36.08 (-0.04), BMY: 75.26 (-0.02)

Jazz Pharmaceuticals Presents New Data from a Human Abuse Liability (HAL) Study for JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy or with Obstructive Sleep Apnea, at 30th Annual SLEEP Meeting
PR Newswire Europe - Tue Jun 14, 8:05AM CDT
Jazz Pharmaceuticals plc today announced results from a Human Abuse Liability (HAL) study of JZP-110, an investigational wake-promoting agent in Phase 3 development for the treatment of excessive sleepiness (ES) in adult patients with narcolepsy or with obstructive sleep apnea (OSA). The data will be presented today at the 30th Associated Professional Sleep Societies (APSS) Annual SLEEP Meeting, taking place June 11-15, 2016 in Denver, Colorado.
JAZZ: 142.40 (+2.52)

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Celator Pharmaceuticals, Inc. - CPXX
ACCESSWIRE - Wed Jun 08, 5:36PM CDT
BALA CYNWYD, PA / ACCESSWIRE / June 8, 2016 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Celator Pharmaceuticals, Inc. ("Celator" or "the Company" (Nasdaq: CPXX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Jazz Pharmaceuticals plc, ("Jazz".
CPXX: 30.25 (+0.01), JAZZ: 142.40 (+2.52)

Biotechnology Equities Technical Notes -- Grifols, Achillion Pharma, Jazz Pharma, and Puma Biotechnology
PR Newswire - Wed Jun 08, 7:25AM CDT
On Tuesday, June 07, 2016, the NASDAQ Composite ended the trading session at 4,961.75, down 0.14%; the Dow Jones Industrial Average advanced 0.10% to finish at 17,938.28; and the S&P 500 closed at 2,112.13, up 0.13%. The gains were broad based as eight out of nine sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Grifols S.A. (NASDAQ: GRFS), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), and Puma Biotechnology Inc. (NYSE: PBYI). Learn more about these stocks by accessing their free trade alerts at:
ACHN: 9.28 (+0.14), JAZZ: 142.40 (+2.52), GRFS: 17.06 (+0.14), PBYI: 35.73 (+0.85)

Celator Pharmaceuticals, Inc. Acquisition May Not Be in the Best Interests of CPXX Shareholders
PR Newswire - Fri Jun 03, 5:21PM CDT
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Celator Pharmaceuticals, Inc. ("CPXX" or the "Company" in connection with the proposed acquisition of the Company by Jazz Pharmaceuticals plc ("Jazz". On May 31, 2016, the Company announced it had reached a definitive agreement for Jazz to acquire all outstanding shares of CPXX pursuant to a tender offer for $30.25 in cash for each share of Company common stock.
CPXX: 30.25 (+0.01), JAZZ: 142.40 (+2.52)

Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) - Pipeline Review, H1 2016 Featuring D-Pharm Ltd. & Jazz Pharmaceuticals Plc - Research and Markets
BusinessWire - Fri Jun 03, 10:52AM CDT
Research and Markets has announced the addition of the "Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) - Pipeline Review, H1 2016" report to their offering.
JAZZ: 142.40 (+2.52)

Jazz Pharmaceuticals Partnering Deals and Alliances 2010 to 2016
PR Newswire - Thu Jun 02, 6:19PM CDT
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies.
JAZZ: 142.40 (+2.52)

CELATOR PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Jazz Pharmaceuticals plc
BusinessWire - Thu Jun 02, 12:22PM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Celator Pharmaceuticals, Inc. ("Celator" (NASDAQ: CPXX) concerning the sale to Jazz Pharmaceuticals plc. Under the terms of the agreement, Celator shareholders will only receive $30.25 in cash for each share owned.
CPXX: 30.25 (+0.01), JAZZ: 142.40 (+2.52)

Company News for June 01, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 9:10AM CDT
Companies in the News are: WR,GXP,MDT,CPXX,JAZZ,VLKAY
CPXX: 30.25 (+0.01), GXP: 30.88 (-0.32), WR: 56.22 (-0.20), MDT: 88.37 (+0.01), JAZZ: 142.40 (+2.52)

Shareholder Alert: Pomerantz LLP Investigates Claims That the Merger May Not Be in the Best Interest of Investors of Celator Pharmaceuticals, Inc. - CPXX
PR Newswire - Tue May 31, 3:29PM CDT
Pomerantz LLP is investigating claims on behalf of investors of Celator Pharmaceuticals Inc. ("Celator" or the "Company" (NASDAQ: CPXX) (ISIN: US15089R1023) (CUSIP: 15089R102) concerning the proposed acquisition of Celator by Jazz Pharmaceuticals plc.
CPXX: 30.25 (+0.01), JAZZ: 142.40 (+2.52)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation Concerning the Fairness of the Sale of Celator Pharmaceuticals, Inc. to Jazz Pharmaceuticals plc - CPXX
ACCESSWIRE - Tue May 31, 11:22AM CDT
NEW YORK, NY / ACCESSWIRE / May 31, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:
CPXX: 30.25 (+0.01), JAZZ: 142.40 (+2.52)

Jazz Pharmaceuticals And Celator Pharmaceuticals Announce Agreement For Jazz Pharmaceuticals To Acquire Celator For $30.25 Per Share
PR Newswire Europe - Tue May 31, 2:30AM CDT
Transaction would add VYXEOS(TM), an investigational product in development as a treatment for Acute Myeloid Leukemia (AML), to Jazz Pharmaceuticals' portfolio
CPXX: 30.25 (+0.01), JAZZ: 142.40 (+2.52)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Jazz Pharmaceuticals plc
BusinessWire - Fri May 27, 1:47PM CDT
Levi & Korsinsky announces it has commenced an investigation of Jazz Pharmaceuticals plc ("Jazz Pharmaceuticals" or the "Company" (NASDAQ:JAZZ) concerning possible violations of federal securities laws.
JAZZ: 142.40 (+2.52)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jazz Pharmaceuticals plc - JAZZ
PR Newswire - Fri May 27, 10:41AM CDT
Pomerantz LLP is investigating claims on behalf of investors of Jazz Pharmaceuticals plc ("Jazz" or the Company) (NASDAQ: JAZZ). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
JAZZ: 142.40 (+2.52)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 137

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 21

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 184

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 319

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 168

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 114

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 196

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 142

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 191

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading

Top 5 Most Recently Viewed Articles

Ryan Specialty Group's Strategic Push with Innovisk Acquisition

Updated Category News Views 151

Ryan Specialty Group's Acquisition Strategy Ryan Specialty Group (NYSE: RYAN), a prominent player in the specialty insurance sector, is on the brink of finalizing its acquisition of Innovisk Capital Partners. This move is primarily aimed at bolstering their underwriting capacity and expanding their overall market presence. The anticipated completion of the transaction is...

Continue Reading
Stifel Adjusts Align Technology Target Amid Restructuring Plans

Updated Category News Views 216

Stifel Adjusts Align Technology Target Price Recently, Stifel revised its outlook on Align Technology (NASDAQ: ALGN), lowering the price target from $285 to $275 while maintaining a Buy rating on the stock. This adjustment reflects the company's third-quarter financial performance, which met the expectations outlined in the analyst's prior survey. Performance Overview The...

Continue Reading
Golf Scramble Fundraiser to Empower Chicago's Youth Programs

Updated Category News Views 161

Golf Scramble Fundraiser to Empower Youth Nonprofit organization buildOn is excited to announce its inaugural Drive for Students Golf Scramble, a unique fundraiser focused on uniting students through service and education. This event is dedicated primarily to empowering young individuals and providing them the necessary tools to make a lasting impact in their communities....

Continue Reading
Key Highlights from Last Year's Most Notable Releases

Updated Category News Views 255

Overview of Press Releases That Made an Impact The past year was filled with significant announcements and updates that captured audience interest across various sectors. From recalls to growth strategies, the stories represented a multitude of companies and their evolving narratives. Top Press Releases of the Year Some highlights from the most widely read releases over...

Continue Reading
Thomas 'Biz Doc' Ellsworth Joins the Private Economic Council

Updated Category News Views 173

Thomas 'Biz Doc' Ellsworth Joins the Private Economic Council The Private Economic Council (PEC), a coalition of prominent economists, entrepreneurs, and policy makers, has welcomed Thomas Ellsworth to its influential roster. This news highlights Ellsworth's perceived value amidst a team dedicated to fostering economic growth. Experience and Background Ellsworth, known as...

Continue Reading